Portal vein thrombosis as a thrombotic complication of COVID-19 mRNA vaccine: A case report and literature review
Prakriti Singh Shrestha,
Angela Ishak,
Arun R. Napit,
Sarosh Sarwar,
Niraj Rai,
Zoha Nizami,
Niharika Bheemisetty,
Prashanth Jayaraj,
Amardeep Shrestha,
Ivan D. Rodriguez
Affiliations
Prakriti Singh Shrestha
Department of Research and Academic Affairs, Larkin Community Hospital, South Miami, FL, USA; Family Medical Clinic, O’Fallon, IL, USA; Corresponding author at: Department of Research and Academic Affairs, Larkin Community Hospital, South Miami, FL, USA.
Angela Ishak
Department of Research and Academic Affairs, Larkin Community Hospital, South Miami, FL, USA
Arun R. Napit
Valley Health and Research Center, Srijananagar, Bhaktapur, Nepal
Sarosh Sarwar
Fazaia Medical College, Islamabad, Pakistan
Niraj Rai
University of Health Sciences, Lahore, Pakistan
Zoha Nizami
Department of Research and Academic Affairs, Larkin Community Hospital, South Miami, FL, USA
Niharika Bheemisetty
Department of Research and Academic Affairs, Larkin Community Hospital, South Miami, FL, USA
Prashanth Jayaraj
Department of Family Medicine, Larkin Community Hospital, South Miami, FL, USA
Amardeep Shrestha
Family Medical Clinic, O’Fallon, IL, USA
Ivan D. Rodriguez
Department of Family Medicine, Larkin Community Hospital, South Miami, FL, USA
Thrombosis following COVID-19 vaccination commonly occurs with vector-based vaccines. The proposed mechanism is vaccine-induced thrombotic thrombocytopenia (VITT), with thrombocytopenia as principal manifestation. We present a 51-year-old male who came with isolated portal vein thrombosis (PVT) one day after Moderna vaccination, without associated thrombocytopenia, challenging VITT as being the only patho-mechanism. Further exploration of these possible alternative mechanisms is needed for COVID-19 vaccine-related thrombotic complications.
